Opportunities and Challenges with Adoption of Immuno-Oncology Drugs and Diagnostics
MattLphotography / Alamy Stock Photo
Checkpoint Inhibitor I-O drugs in the market In cancer, immune checkpoint pathways are often activated to inhibit the nascent anti-tumor immune response. Immune checkpoint therapies act by blocking or stimulating these pathways and enhance the body’s immunological activity against tumors. CTLA-4, PD-1, and PD-L1 are the most widely studied and recognized inhibitory checkpoint pathways. CTLA-4 […]